Nearly seven decades after a sedative the government never approved was handed to pregnant women across America, the children who were born with shortened, misshapen limbs are in their 60s — and they want the federal government to formally acknowledge they exist. Advocates who have spent years documenting those cases say the official count of thalidomide survivors in the United States is too low, and that the discrepancy reflects a story the country has spent decades minimizing.
The episode begins in late 1960, when the Cincinnati-based pharmaceutical company William S. Merrell applied to the Food and Drug Administration for approval of a German-made sedative. The company expected the application to move quickly through review and reach store shelves before Christmas. It would not happen. The drug, thalidomide, was not approved that year, nor in the year that followed.
The person credited with blocking that approval was Dr. Frances Oldham Kelsey, a pharmacologist and medical reviewer at the agency. In a widely reproduced photograph taken Oct. 15, 1962, Kelsey is pictured in Washington holding three packages of Contergan, the German brand name for thalidomide. Kelsey prevented the FDA from approving the drug for general use in the United States.
Kelsey's insistence on a closer look at the drug is routinely credited with reshaping the agency's testing and approval process, producing the more rigorous regulatory system that exists today. In the years since, the thalidomide episode has become shorthand for why modern drug law demands evidence of safety before a medicine reaches patients, and Kelsey became an emblem of bureaucratic vigilance. President John F. Kennedy publicly praised her at a press conference, crediting her with sparing the United States "this terrible human tragedy which has been visited on families in Germany."
But as survivors and historians have documented, the heroic version of that story is only partly complete. Even as the FDA application stalled, doctors in the United States were already administering thalidomide to thousands of patients, including women who were pregnant. Some of the children those women carried were born with severely deformed limbs. Those children are now adults, and they are the ones now asking the government to formally acknowledge their existence.
The gap between the official record and the lived one is where the current fight sits. According to reporting from Ohio Newsroom and its Staten News service, which has followed the campaign for recognition, the number of thalidomide survivors in the U.S. exceeds what federal authorities have acknowledged. Advocates say the undercount is not necessarily a deliberate judgment so much as the residue of decades without a central registry, scattered medical records, and early stigma that discouraged families from documenting their children's conditions.
Phocomelia, the signature limb deformity caused by thalidomide, is rare in general — but it is slightly more common outside the United States, in countries such as Britain and Germany, where the drug was sold far more widely and for far longer. That contrast has long been used to argue that the American experience was a footnote rather than a chapter. Survivors push back on that reading.
"We go to doctors today who say it didn't happen here in the United States. Oh yeah, it did," said Gwen Riechmann, who was born with phocomelia. Riechmann's mother became pregnant with her in the early 1960s, and, as Riechmann has recounted, her doctor gave her a new sedative for the pregnancy — a drug that had never been cleared for general U.S. use, and one Riechmann was not told about.
That kind of clinical encounter was possible because the regulatory landscape of the time allowed physicians to obtain and administer unapproved drugs. Reforms to how the FDA evaluates and approves medicines grew out of precisely this era; the 1962 Kefauver-Harris amendments overhauled requirements for demonstrating safety and effectiveness after high-profile drug failures. In the years before those reforms, there was no equivalent backstop forcing a woman pregnant in Ohio, Indiana or Pennsylvania to learn what was in the pill she was handed.
For survivors, the consequences of that history are not only physical. Many describe a lifetime of medical encounters in which their deformities were misread, misdiagnosed, or attributed to causes other than thalidomide. A doctor's later insistence that the drug never touched American patients is, to them, not a technicality but a second injury — one that follows them into exam rooms long after the pregnancy that caused it is a half-century past.
The push for recognition is part legal, part moral, and partly a request for simple documentation: a federal acknowledgment, a more accurate count, and a public account that matches the one survivors themselves have been keeping. Recognition would not repair what thalidomide did. But it would end the practice of treating a documented American tragedy as a foreign one — a distinction that Riechmann's generation says is not merely inaccurate, but actively harmful to people still seeking care.
The timing is pointed. Kelsey's stand is celebrated as a high-water mark of American drug regulation, a story in which one official's caution saved a country. Survivors' families and advocates note that the same system that produced a legacy of scientific safeguards also left thousands of women, and the children they were carrying, outside the protections those safeguards were later built to guarantee. Both truths are part of the record, and the survivors now in their late 60s are asking that officials stop telling only one of them.
(0)